Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SAR445399
- Development stage
- Phase 2
- Lead developer
- Sanofi
- Modality
- Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous, Subcutaneous
01
Overview
SAR445399 is an investigational trivalent nanobody developed by Sanofi that simultaneously targets and neutralizes three potent pro-inflammatory cytokines: tumor necrosis factor-alpha (TNF-α), interleukin-17A (IL-17A), and interleukin-17F (IL-17F). Utilizing technology acquired from Ablynx, this multi-specific biologic is designed to offer a more comprehensive inhibition of inflammatory pathways than traditional single-target agents. It is currently being evaluated for its efficacy and safety in treating chronic inflammatory conditions, with a primary focus on moderate to severe hidradenitis suppurativa (HS), a disease where TNF and IL-17 signaling are known to drive significant tissue inflammation and lesion formation.
02
Targets
IL1RAP (Interleukin 1 receptor accessory protein)IL-17A (Interleukin-17A)IL17F (Interleukin 17F)TNFA (Tumor necrosis factor alpha (soluble))
Beyond the preview
Go deeper on SAR445399.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SAR445399.